Paul Lammers

President & Chief Executive Officer
Triumvira Immunologics
Philipp Nold
Dr. Lammers, MD, MSc, joined Triumvira Immunologics as President, CEO, and Director in January 2018. Before joining Triumvira, Dr. Lammers served as President/CEO/Director at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing on NASDAQ. Previously, he served as President of Repros Therapeutics and also 6 years as Chief Medical Officer and Head of US Product Development for EMD Serono (Merck KgA). During his early industry tenure, Dr. Lammers also held various executive and senior management positions in clinical development, medical affairs, and regulatory affairs at both medium and large pharmaceutical companies, as well as at small public and privately held biotech companies. Dr. Lammers currently serves as Lead Independent Director of Salarius Pharmaceuticals, on the Board of Directors of ImmunoMet, and as a Member of the Product Development Advisory Committee of CPRIT, the Cancer Prevention and Research Institute of Texas.


October 29 2019, 13:50
 - 14:20
Co-Opting The Natural T-Cell Receptor: A Step Forward In Adoptive T Cell Therapy